Report cover image

Short Bowel Syndrome Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Sep 01, 2024
Length 127 Pages
SKU # FOB19185709

Description

Short Bowel Syndrome Market



Growth Factors of Short Bowel Syndrome Market

The short bowel syndrome market size was valued at USD 1.01 billion in 2023, and the market is now projected to grow from USD 1.15 billion in 2024 to USD 3.36 billion by 2032, exhibiting a CAGR of 14.3% during the forecast period of 2023-2030.

The COVID-19 pandemic created significant challenges on the operative elective surgeries as curbing coronavirus outbreak was prioritized over the surgeries that were not life-threatening unlike COVID. Therefore a huge decline in the elective procedures, operative dental procedures, orthopedic surgeries as well as emergency room visits in the hospitals and operation theatres were on a hold for a significant amount of period that caused an immense downfall in terms of number of post-operative surgeries during the pandemic period, impeding the rise of medical devices market growth.

GLP-2 Drugs' increasing penetration for SBS intestinal failure (SBS-IF) promoting short bowel syndrome market growth. A uncommon disorder called SBS-IF is brought on by short bowel syndrome in patients. Parenteral support must be administered more frequently to patients with this illness. Typically, this medication is given five days a week on average. But continuous parenteral support use is impeding the patient's everyday activities, raising the hospitalization rate, and causing problems related to this therapy, which is driving the market uptake of GLP-2-based medications. Additionally, it is anticipated that during the forecast period, developed countries will see a rise in the penetration of GLP-2 medications. This is because pipeline candidates have a number of advantages, including decreased hospitalization rates and better dosing frequency.

Change the treatment of SBS from total parenteral nutrition to GLP-2drugs will promote market growth. The market has seen a preference for GLP-2 medications over Total Parenteral Nutrition (TPN) in recent years for the treatment of the illness. This is because using parenteral nutrition therapy over an extended period of time might lead to a number of problems. Sepsis from the catheter and problems with the liver and kidneys are risk factors for whole parenteral feeding. As a result, novel medications that help lower the need for parenteral support generally being used to treat this syndrome.

Comprehensive Short Bowel Syndrome Market

The short bowel syndrome market and pharmaceutical industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types and by distribution channel. The types segmentation includes, GLP-2, Growth Hormone, Glutamine, and Others, while By Distribution Channel segmentation include Hospital Pharmacies and Online & Retail Pharmacies.

The North America region lead the short bowel syndrome market by benefitting a market size of USD 0.75 billion in 2023 due to a sizable patient population using cutting-edge medications and needing innovative therapeutic approaches prolonged use of licensed medications to treat patients in both adult and pediatric settings, as well as a large number of pipeline items.

The prominent players in the market play a crucial role in the pharmaceutical industry assuring industrial prospectus growth and setting market standards. These key industry players include, VectivBio AG (Switzerland), Hanmi Pharm Co., Ltd. (South Korea), Takeda Pharmaceutical Company Limited (Japan), OxThera (Sweden), Zealand Pharma A/S (Denmark), 9 Meters Biopharma, Inc. (U.S.), and Nestlé Health Science (Switzerland) these market players provide a level-playing competitive environment across the globe.

In June 2022, one of the major industry player, has introduced its promising findings of Vurolenatide's phase 2 clinical trial in the treatment of this syndrome were revealed by 9 Meters Biopharma, Inc.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 14.3% from 2024-2032

Unit Value (USD billion)

Segmentation By Type

- GLP-2

- Growth Hormone

- Glutamine

- Others

By Distribution Channel

- Hospital Pharmacies

- Online & Retail Pharmacies

By Geography

- North America (By Type, By Distribution Channel, By Country)
  • U.S.
  • Canada
- Europe (By Type, By Distribution Channel, By Country/Sub-Region)
  • Germany
  • U.K
  • France
  • Italy
  • Russia
  • Rest of Europe
- Asia Pacific (By Type, By Distribution Channel, By Country/Sub-Region)
  • India
  • China
  • Japan
  • Australia
  • Southeast Asia
  • South Korea
  • Rest of Asia Pacific
- Latin America (By Type, By Distribution Channel, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
- Middle East & Africa (By Type, By Distribution Channel, By Country/Sub-Region)
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Table of Contents

127 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Global Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
4.1. Market Analysis, Insights and Forecast – By Type
4.1.1. GLP-2
4.1.2. Growth Hormone
4.1.3. Glutamine
4.1.4. Others
4.2. Market Analysis, Insights and Forecast – By Distribution Channel
4.2.1. Hospital Pharmacies
4.2.2. Online & Retail Pharmacies
4.3. Market Analysis, Insights and Forecast – By Region
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East and Africa
5. North America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. GLP-2
5.1.2. Growth Hormone
5.1.3. Glutamine
5.1.4. Others
5.2. Market Analysis, Insights and Forecast – By Distribution Channel
5.2.1. Hospital Pharmacies
5.2.2. Online & Retail Pharmacies
5.3. Market Analysis, Insights and Forecast – By Country
5.3.1. U.S.
5.3.2. Canada
6. Europe Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. GLP-2
6.1.2. Growth Hormone
6.1.3. Glutamine
6.1.4. Others
6.2. Market Analysis, Insights and Forecast – By Distribution Channel
6.2.1. Hospital Pharmacies
6.2.2. Online & Retail Pharmacies
6.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
6.3.1. Germany
6.3.2. U.K
6.3.3. France
6.3.4. Italy
6.3.5. Russia
6.3.6. Rest of Europe
7. Asia Pacific Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. GLP-2
7.1.2. Growth Hormone
7.1.3. Glutamine
7.1.4. Others
7.2. Market Analysis, Insights and Forecast – By Distribution Channel
7.2.1. Hospital Pharmacies
7.2.2. Online & Retail Pharmacies
7.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.3.1. India
7.3.2. China
7.3.3. Japan
7.3.4. Australia
7.3.5. Southeast Asia
7.3.6. South Korea
7.3.7. Rest of Asia Pacific
8. Japan Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. GLP-2
8.1.2. Growth Hormone
8.1.3. Glutamine
8.1.4. Others
8.2. Market Analysis, Insights and Forecast – By Distribution Channel
8.2.1. Hospital Pharmacies
8.2.2. Online & Retail Pharmacies
9. Latin America Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. GLP-2
9.1.2. Growth Hormone
9.1.3. Glutamine
9.1.4. Others
9.2. Market Analysis, Insights and Forecast – By Distribution Channel
9.2.1. Hospital Pharmacies
9.2.2. Online & Retail Pharmacies
9.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.3.1. Brazil
9.3.2. Mexico
9.3.3. Argentina
9.3.4. Colombia
9.3.5. Rest of Latin America
10. Middle East & Africa Short Bowel Syndrome Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. GLP-2
10.1.2. Growth Hormone
10.1.3. Glutamine
10.1.4. Others
10.2. Market Analysis, Insights and Forecast – By Distribution Channel
10.2.1. Hospital Pharmacies
10.2.2. Online & Retail Pharmacies
10.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
10.3.1. Turkey
10.3.2. Saudi Arabia
10.3.3. UAE
10.3.4. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. Takeda Pharmaceutical Company Limited
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. OxThera
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Zealand Pharma A/S
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. VectivBio AG
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Hanmi Pharm.Co.,Ltd.
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. 9 Meters Biopharma, Inc.
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. Merck KGaA
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Emmaus Medical, Inc.
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Nestlé Health Science
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us